BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,427,000 | +6.6% | 9,437 | +2.7% | 0.01% | +16.7% |
Q2 2022 | $1,339,000 | +35.5% | 9,192 | +10.4% | 0.01% | +50.0% |
Q1 2022 | $988,000 | -60.0% | 8,329 | -53.5% | 0.01% | -11.1% |
Q4 2021 | $2,468,000 | +96.5% | 17,906 | +98.1% | 0.01% | -18.2% |
Q3 2021 | $1,256,000 | +38.5% | 9,041 | -3.3% | 0.01% | +57.1% |
Q2 2021 | $907,000 | +93.8% | 9,347 | +36.5% | 0.01% | -61.1% |
Q1 2021 | $468,000 | -27.3% | 6,850 | -8.9% | 0.02% | -25.0% |
Q4 2020 | $644,000 | +32.5% | 7,518 | +0.5% | 0.02% | +14.3% |
Q3 2020 | $486,000 | -12.0% | 7,478 | -0.9% | 0.02% | -19.2% |
Q2 2020 | $552,000 | +119.9% | 7,549 | +2.5% | 0.03% | +333.3% |
Q1 2020 | $251,000 | -35.6% | 7,367 | +2.8% | 0.01% | -14.3% |
Q4 2019 | $390,000 | +42.9% | 7,169 | +9.4% | 0.01% | +16.7% |
Q3 2019 | $273,000 | +4.6% | 6,554 | +9.9% | 0.01% | 0.0% |
Q2 2019 | $261,000 | +7.4% | 5,966 | +26.6% | 0.01% | 0.0% |
Q1 2019 | $243,000 | – | 4,714 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |